According to the decision, Bayer must license the drug Nexavar, or sorafenib, to Natco Pharma, an Indian company. In exchange, Natco must pay Bayer a 6 percent royalty on its net sales and has to sell the drug for 8,800 rupees ($176) a month, about 3 percent of the 280,000 ($5866) rupees that Bayer charges for it in India. Natco’s drug is for use only in India, the decision said.In 2011, India's GDP PPP per capita was $3,703 and actual per capita income was about $1100.
So the monthly cost of the Bayer drug was nearly twice the GDP PPP per capita and over five times the actual per capita income.